Structural basis of SARM1 activation, substrate recognition, and inhibition by small molecules

Mol Cell. 2022 May 5;82(9):1643-1659.e10. doi: 10.1016/j.molcel.2022.03.007. Epub 2022 Mar 24.

Abstract

The NADase SARM1 (sterile alpha and TIR motif containing 1) is a key executioner of axon degeneration and a therapeutic target for several neurodegenerative conditions. We show that a potent SARM1 inhibitor undergoes base exchange with the nicotinamide moiety of nicotinamide adenine dinucleotide (NAD+) to produce the bona fide inhibitor 1AD. We report structures of SARM1 in complex with 1AD, NAD+ mimetics and the allosteric activator nicotinamide mononucleotide (NMN). NMN binding triggers reorientation of the armadillo repeat (ARM) domains, which disrupts ARM:TIR interactions and leads to formation of a two-stranded TIR domain assembly. The active site spans two molecules in these assemblies, explaining the requirement of TIR domain self-association for NADase activity and axon degeneration. Our results reveal the mechanisms of SARM1 activation and substrate binding, providing rational avenues for the design of new therapeutics targeting SARM1.

Keywords: ARM domain; NADase; TIR domain; X-ray crystallography; allosteric activator; base exchange; cryo-EM; orthosteric inhibitor.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Armadillo Domain Proteins* / genetics
  • Cytoskeletal Proteins / chemistry
  • Cytoskeletal Proteins / genetics
  • NAD* / metabolism
  • NAD+ Nucleosidase / metabolism
  • Protein Domains

Substances

  • Armadillo Domain Proteins
  • Cytoskeletal Proteins
  • NAD
  • NAD+ Nucleosidase